ABSTRACT: Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor (GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reduction for the treatment of type 2 diabetes mellitus by glucose-dependent control of insulin and glucagon secretion. GLP-1R agonists also decelerate gastric emptying, reduce body weight by reduction of food intake and lower circulating lipoproteins, inflammation, and systolic blood pressure. Preclinical studies demonstrate that both GLP- found that these agents neither increased nor decreased cardiovascular events. Here we review the cardiovascular actions of GLP-1R agonists and DPP-4 inhibitors, with a focus on the translation of mechanisms derived from preclinical studies to complementary findings in clinical studies. We highlight areas of uncertainty requiring more careful scrutiny in ongoing basic science and clinical studies. As newer more potent GLP-1R agonists and coagonists are being developed for the treatment of type 2 diabetes mellitus, obesity, and nonalcoholic steatohepatitis, the delineation of the potential mechanisms that underlie the cardiovascular benefit and safety of these agents have immediate relevance for the prevention and treatment of cardiovascular disease.
G lucagon-like peptide-1 (GLP-1) was initially discovered as an insulinotropic hormone produced in and secreted from the gut after food intake. 1 It has received attention because of its role in the physiology of glucose metabolism (ie, its function as an incretin 2 ) but more so as a parent compound mediating the actions of 2 classes of glucose-lowering medications used in the treatment of type 2 diabetes mellitus (T2D), GLP-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase-4 inhibitors (DPP-4Is).
1 GLP-1R agonists, either small peptides or much larger peptidomimetics, mediate their glucoregulatory actions by a single GLP-1R. In contrast, inhibitors of the protease DPP-4 prevent the degradation and inactivation of both GLP-1 and the incretin hormone glucose-dependent insulinotropic polypeptide. 1 GLP-1R agonists and DPP-4Is are approved for the treatment of hyperglycemia in patients with T2D. 2 Although glycemic control reduces the microvascular complications of diabetes mellitus (neuropathy, nephropathy, and retinopathy), the relationship between glucose control and reduction of macrovascular events is more challenging. 3 It is notable that incretin-based therapies (GLP-1R agonists [GLP-1RAs] and DPP-4Is) exert multiple nonglycemic actions in the cardiovascular system, heightening the interest in their potential for cardiovascular benefit. [4] [5] [6] The recent findings that 2 GLP-1RAs, liraglutide 7 and semaglutide, 8 significantly reduced the combined primary outcome of 3 point major adverse cardiovascular events in large cardiovascular outcome trials elevates the importance of understanding how activation of the GLP-1R translates into clinical cardiovascular benefit. The purpose of the present review is to summarize the literature on indirect (through lowering glucose and modifying known cardiovascular risk factors) and direct (through stimulating GLP-1Rs and inhibition of DPP-4) effects of (1) GLP-1, (2) GLP1RAs, and (3) DPP-4Is on the heart and blood vessels. Herein we discuss concepts of incretin action in the context of results of cardiovascular outcomes trials with DPP-4Is and GLP-1RAs and, wherever possible, link underlying mechanisms to observed clinical benefits.
GLP-1RS IN THE CARDIOVASCULAR SYSTEM AND EFFECTS ELICITED BY STIMULATING WITH GLP-1, GLP-1RAS, OR DPP-4IS (PRECLINICAL STUDIES) GLP-1Rs in the Cardiovascular System
GLP-1R expression has been detected in various cardiovascular tissues and cell types at the mRNA and protein levels. Although native GLP-1 improves endothelial function, augments ventricular contractility, enhances myocardial glucose uptake, and exerts cytoprotective and metabolic actions on blood vessels and cardiomyocytes, the endogenous canonical GLP-1R is not highly expressed in many of the cell types responsive to GLP-1 or GLP-1RAs. Hence, some of the well-described actions of GLP-1 in preclinical studies may reflect indirect mechanisms or the actions of ≥1 GLP-1 degradation products acting through GLP-1R-independent mechanisms. Details are summarized in Table I in the online-only Data Supplement, which highlights well-documented effects on the heart (contractile function, substrate supply, coronary and myocardial blood flow, rate control), blood pressure, and platelet aggregation. Because the present review is focused on human studies, we refer to Table I and accompanying text in the online-only Data Supplement and several recent reviews for details of preclinical studies. [4] [5] [6] 9, 10 
Potential Mechanisms Explaining Biological Effects of N-Terminal GLP-1 Fragments GLP-1 [9-36] Amide, GLP-1 [9-37], or GLP-1 [28-36] Amide
Considerable evidence supports biological activity for N-terminally truncated GLP-1 peptides, principally GLP-1 amide 10, 11 and GLP-1 [28] [29] [30] [31] [32] [33] [34] [35] [36] amide 12 in the cardiovascular system. Although a distinct receptor for these peptides has not been identified, they successfully target cytoplasmic and mitochondria-linked pathways, leading to a reduction of reactive oxygen species in hepatocytes, endothelial cells, and cardiomyocytes. 10, 11 Moreover, GLP-1 [28] [29] [30] [31] [32] [33] [34] [35] [36] directly activates prosurvival kinases in the ischemic mouse heart or vascular cells through mechanisms linked to soluble adenylate cyclase and cAMP generation in isolated cardiomyocytes ex vivo. 12 Hence, studies using native GLP-1 may be associated with activation of dual cardiovascular pathways mediated through the classical GLP-1R and nonclassical cAMP-mediated pathways activated by truncated peptides converging on cardiomyocyte and vascular protection. 10 
DPP-4 in the Cardiovascular System
DPP-4 is widely expressed in most cells and tissues and exhibits enzymatic activity against dozens of chemokines and peptide hormones with roles in inflammation, vascular function, stem cell homing, and cell survival. 13 DPP-4 exhibits exopeptidase activity through its 2 principal molecular forms, a membrane-tethered 766 amino acid protein with a small intracellular tail and a soluble form that is 39 amino acids smaller, devoid of the short membrane spanning domain and intracellular tail, and yet otherwise structurally identical. 13 Although soluble DPP-4 exerts vascular, immune, and proinflammatory actions independent of its catalytic activity, the majority of the experimental literature has studied the importance of DPP-4-mediated peptide cleavage in the pathophysiology and treatment of cardiovascular disease.
Attribution of mechanism(s) linking reduction of DPP-4 activity to attenuation of cardiovascular injury or preservation of cardiovascular function is difficult for several reasons. First, DPP-4 cleaves dozens of substrates simultaneously, initiating complex changes in multiple signaling pathways. 4, 5 Second, the majority of DPP-4 substrates circulate at low levels and are difficult to quantitate. Third, highly sensitive and specific assays distinguishing full length from DPP-4-cleaved peptides are generally not commercially available. Hence, measurements of total immunoreactive peptide detect a mixture of cleaved versus intact substrates. Fourth, many of the DPP-4-cleaved peptide metabolites retain biological activity in the cardiovascular system, albeit through different receptors and signaling pathways. Hence, DPP-4 simultaneously inactivates and potentiates the activity of numerous cardioactive substrates. 5, 13 Last, only a few highly selective antagonists for DPP-4 peptide substrates are available, and these reagents have not been widely used in cardiovascular studies.
Preclinical Effects in Myocardial Infarction Models and Cardiovascular Function
When myocardial infarction is experimentally induced by occluding (ligating) a coronary artery, the myocardial area receiving blood supply through the vessel to be occluded can be defined as an area at risk, and the resulting area of necrosis can be identified by specific staining methods.
14 Administration of GLP-1, GLP1RAs (eg, exenatide, liraglutide), and DPP-4Is (eg, sitagliptin, vildagliptin, alogliptin) reduces the resulting necrosis (relative to the area at risk), as summarized in Figure I in the online-only Data Supplement. Examples encompass in vivo and ex vivo (isolated perfused heart) studies, studies in rodents and larger mammals, and with various pharmacological agents (GLP-1 [7-36 amide] , DPP-4Is, and GLP-1RAs) ( Figure I in the onlineonly Data Supplement). Additional studies examining effects of the GLP-1RAs exenatide, 15 lixisenatide, 16 and albiglutide 17 and the DPP-4Is sitagliptin 18 and linagliptin 19 have been published. Although occasional reports do not replicate these findings (eg, with liraglutide in a porcine model 20 ) , the majority of studies found a significant reduction in the necrotic area in hearts of animals treated with GLP-1 or GLP-1RAs ( Figure I in the online-only Data Supplement). The cardioprotective effects of GLP-1 can be inhibited by the specific GLP-1RA exendin . Thus, these effects seem to be mediated by an interaction with the canonical GLP-1R.
14 More details are described in the online-only Data Supplement. 
CARDIOVASCULAR ACTIONS IN HUMANS

GLP-1R in Human Cardiovascular Tissues
The atrial expression of the GLP-1R protein was identified in nonhuman primate and human hearts using a highly specific monoclonal antibody, localizing an immunoreactive GLP-1R protein to cells within the sinoatrial node. 21 Nevertheless, some studies have detected partial GLP-1R mRNA transcripts by reverse transcription polymerase chain reaction techniques using RNA isolated from human ventricles, although GLP-1RAs such as exenatide failed to augment contractility in the majority of isolated strips from human ventricles in the same experiments. 27 RNASeq analyses have detected the presence of GLP-1R mRNA transcripts in RNA from human left ventricles (http://www.gtexportal.org/ home/gene/GLP1R). Hence, these findings imply that under some circumstances, transcriptional or translational control may dictate whether a ventricular GLP-1R mRNA transcript is expressed and gives rise to functional GLP-1R protein in the human heart (including the working myocardium in atria and ventricles). The presence or absence of a functional GLP-1R in human coronary arteries is not clearly established. 6 
Cardiac Output
Intravenous GLP-1 at a pharmacological dose improved left ventricular function, maximum oxygen uptake, and physical performance in subjects with congestive heart failure. 25 Likewise, intravenous exenatide (GLP-1RA) improved cardiac index and pulmonary capillary wedge pressure and reduced atrial natriuretic peptide. 28 However, in vitro, exenatide increased contractility in human atrial but not ventricular myocardium. 27 Larger randomized controlled clinical trials with albiglutide or liraglutide failed to demonstrate any beneficial effect of sustained GLP-1RA treatment in human subjects with moderate to severe heart failure and reduced ejection fraction, 29, 30 independent of the presence or absence of diabetes mellitus. In patients with advanced heart failure, liraglutide did not improve a composite end point of cardiovascular events that included changes in N-terminal pro-brain natriuretic peptide. A numeric but statistically nonsignificant increase in mortality and hospitalization for heart failure was detected (hazard ratio [HR], 1.30; 95% confidence interval [CI], 0.92-1.83; P=0. 14) , indicating a potential for harm in patients with reduced ejection fraction and a prior history of hospitalization for heart failure. It is possible that this may be related to ; intravenous: cardiac index ↑, PCWP ↑, and ANP ↓
28
• Albiglutide: no significant effects 29 • Liraglutide: trend for reduced rate of hospitalization for congestive heart failure (LEADER) 7 ; however, trends for worse outcomes (not significant) in dedicated heart failure trials 30, 31 • Sitagliptin (chronic congestive heart failure): left ventricular diastolic function ↑
32
• Rate of hospitalization for congestive heart failure ≈ (TECOS) 33 • Saxagliptin: rate of hospitalization for congestive heart failure ↑ (significant) SAVOR-TIMI 53 34, 35 • Alogliptin: rate of hospitalization for congestive heart failure ↑ (nonsignificant) EXAMINE 36, 37 • • ↓ by 2-3 mmHg 49, 50 • Occasional reports of lowering systolic blood pressure in hypertensive subjects 52 Natriuretic peptides • ANP ≈ (n.s.) 71, 73 • Liaglutide: pro-ANP ↓, 74 but ANP and pro-BNP ≈ 75, 76 ; ANP ↑ and BNP ↑ also reported increases in heart rate or development of arrhythmias. 30 Coronary blood flow was not changed by liraglutide treatment (Table 1 ). In contrast, in a small pilot study of 18 subjects with T2D treated with sitagliptin for 24 weeks, an improvement in diastolic but not systolic ventricular function was shown. 32 Intravenous GLP-1 and exenatide (GLP-1RA) did not affect myocardial glucose uptake 22, 23 (Table 1) , whereas treatment with the DPP-4I sitagliptin increased myocardial glucose uptake (in subjects without diabetes mellitus with nonischemic cardiomyopathy 24 ; Table 1 ). Overall, GLP-1RA use in human subjects with or without diabetes mellitus does not appear detrimental to cardiac function, except for patients with advanced heart failure. The effects of DPP-4Is in short-term mechanistic studies have to be reconciled with the observation that the DPP-4 I saxagliptin significantly increased the risk for hospitalization for congestive heart failure in the SAVOR TIMI 53 trial 35 (vide infra in the section on clinical trial results).
Ischemic Conditioning
Intravenous GLP-1 improved left ventricular ejection fraction and regional contractility during dobutamine-induced stress and preserved left ventricular function during coronary balloon occlusion. 38, 39 Perioperative intravenous infusions of GLP-1 during and after aortocoronary bypass grafting did not result in changes in left ventricular ejection fraction or cardiac index but reduced the need for inotropic medications. 108 In a pilot study with a small number of patients with and without diabetes mellitus, 72 hours of intravenous GLP-1 infusion to patients with acute myocardial ischemia undergoing percutaneous revascularization improved left ventricular ejection fraction and regional wall motility. 41 Similar evidence with GLP-1RAs suggests an improved salvage of myocardium at risk for necrosis with intravenous exenatide 42 and a reduced infarct size with subcutaneous exenatide. 43 Liraglutide treatment reduced the resulting necrotic area 109 and improved left ventricular ejection fraction after percutaneous intervention for ST-segment elevation 44 and non-ST-segment elevation myocardial infarction. 45 The DPP-4I sitagliptin improved left ventricular ejection fraction and regional contractility during dobutamine-induced stress, 46 with a preferential effect in ischemic segments of the heart.
Heart Rate
Changes in heart rate have not been consistently described with intravenous infusions of GLP-1, at both physiological and pharmacological concentrations. However, a small rise in heart rate (usually by 2-3 beats per minute) has been described in short-term controlled studies with a GLP-1RA ( Figure 1 ). Studies using ambulatory 24-hour monitoring have found larger average changes in heart rate of up to 9 beats per minute. 110 Also, 24-hour monitoring shows that variation in duration of heart rate changes may exist depending on the exposure to the GLP-1RA. Thus, long-acting GLP-1RAs elevate heart rate for 24 hours, whereas short-acting compounds only lead to a transient rise in heart rate for the period characterized by effective drug levels. 110 The relative contributions of the autonomic nervous system (as suggested by a study of exenatide 51 ), versus the direct actions of GLP-1RAs on the GLP-1R located in the sinoatrial node, 21 on heart rate ( Figure 1 ) is difficult to ascertain in human subjects ( Table 1 ). The functional consequences, if any, of longer term increases in heart rate in subjects treated with GLP-1RAs are not entirely known. Although such an increment in heart rate does not seem to prevent overall beneficial results in terms of clinical end points in the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) 7 and SUSTAIN-6 trial (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes), 8 we do not know whether patients with more marked increments in heart rate exhibit different outcomes compared with those with no or less marked increments. Additional analyses will be required to clarify the clinical consequences of changes in heart rate with GLP-1RA treatment.
Effects on the Endothelium
GLP-1 and the GLP-1RA exenatide stimulate proliferation of human endothelial cells in ex vivo studies (Table 1). This finding suggests a possible effect of GLP-1 on new vessel formation, but similar results have not been reported for DPP-4Is. GLP-1 and the GLP-1RAs exenatide and liraglutide increased nitric oxide synthase activity in human endothelial cells 58, 62 (Table 1) . Furthermore, intravenous GLP-1 improves endothelial function, 56, 57 and the GLP-1RA liraglutide augmented acetyl choline-induced vasodilation. 63 The effect of liraglutide alone on endothelial function, which is relatively resistant to degradation by DPP-4 and thus does not form significant amounts of the DPP-4 metabolite, was not significant 65 (Table 1) . This finding could mean that peptides structurally related to GLP-1 amide or GLP-1 are needed for this effect (vide supra). Intravenous exenatide increased myocardial blood flow. 23 Exenatide improved endothelial function after a lipidrich meal 84 , and a single subcutaneous dose of exenatide reduced peripheral vascular resistance. The DPP-4I sitagliptin improved flow-mediated vasodilation in subjects with T2D. 65 However, other studies did not confirm beneficial effects of DPP-4Is on endothelial function 66, 67 ( Table 1) . In contrast to endothelium-dependent vasodilation, endothelium-independent vasodilation (induced by nitroglycerin or nitroprusside) has not been changed with either GLP-1 56 or DPP-4Is. 65 Liraglutide reduced endothelin-1, a peptide able to induce vasoconstriction, in human umbilical vein endothelial cells 62 (Table 1) . Evidence suggests that with both GLP-1RAs (liraglutide) 68 and DPP-4Is (sitagliptin 69 and linagliptin 70 ), treatment may reduce intimamedia thickness or slow the progressive increment in intimamedia thickness, indicating interference with the progression of atherosclerosis. Collectively, although native GLP-1 consistently improves endothelial function independent of changes in insulin or glucose in human studies, insufficient evidence supports a similar benefit on endothelial function in human subjects with diabetes mellitus treated with degradation-resistant GLP-1RAs or DPP-4Is. The placebo-subtracted differences to baseline (± standard error of the mean) are shown for glycohemoglobin (A), body weight (B), systolic blood pressure (C), pulse rate (D), serum triglycerides (E), low-density lipoprotein (LDL) cholesterol (F), and high-density lipoprotein (HDL) cholesterol (G). BID indicates twice daily; q.w., once weekly. *Significant difference (P<0.05).
†Median instead of mean value reported. ‡Based on 24-hour monitoring. §Reported as no relevant change in vital parameters or lipid levels. Data displayed in Figure 2 ) and (Continued )
Blood Pressure
Systolic blood pressure (BP) may transiently rise with acute exposure to pharmacological but not physiological concentrations of (intravenous) GLP-1 or GLP-1RAs (Table 1) .
More sustained treatment with GLP-1RAs consistently leads to a reduction in systolic BP by 2 to 3 mm Hg in subjects with hypertension ( Figure 2 ). Diastolic BP is less consistently affected. DPP-4Is have no uniform BP-lowering effect, but in patients with arterial hypertension, lowering of systolic BP has been reported. 52 Although a role for atrial natriuretic peptide leading to vasodilation and renal sodium excretion has been delineated in rodents, 111 the existence of a GLP-1R-ANF axis has not been uniformly replicated in human subjects with hypertension and T2D (Table 1) , 73, 76 suggesting that atrial natriuretic peptide secretion does not mediate the GLP-1-mediated reduction of BP in obese subjects or those with diabetes mellitus. A rise in atrial natriuretic peptide or brain natriuretic peptide levels has not been consistently reported with liraglutide 74, 75 (Table 1) , but a rise in atrial natriuretic peptide has been observed with exenatide treatment. 112 Nevertheless, acute or chronic GLP-1RAs promote natriuresis in healthy patients, obese patients, or those with diabetes mellitus. 6, 76 Whether the magnitude of the natriuresis is sufficient to contribute to the reduction of BP and cardiovascular events is not clear. These decreases in BP may potentially be mediated by reductions in angiotensin II concentrations 113 or the local release of nitric oxide, which results in vasodilatation (Table 1) .
Renal Function
Intravenous GLP-1 may acutely raise glomerular filtration rates, 78 whereas exenatide did not change glomerular filtration 79 (Table 1) . Liraglutide significantly reduced albuminuria in short-term studies and in the LEADER trial. 7, 74 Small reductions in albuminuria or favorable changes between the categories of micro-and microalbuminuria have also been described for the DPP-4Is saxagliptin 34, 114 and linagliptin. 115 There have been no clinically significant changes in GFR or other renal events in randomized controlled trials of DPP-4 inhibition.
Metabolism
Apart from the well-known effects of GLP-1 and the incretin-based glucose-lowering medications on plasma glucose and HbA 1c levels (Figure 1 ), GLP-1 may transiently reduce the concentrations of nonesterified fatty acids. 82 Effects of incretin-based medications on fasting lipids and lipoproteins, most evident after weight loss, are shown in Figure 1 . The most compelling effect of GLP-1, GLP-1RAs (exenatide, liraglutide), and DPP-4Is (sitagliptin, vildagliptin, alogliptin) has been a reduction in the postprandial rise in triglycerides and apolipoprotein-B 48, constituents of intestinally derived chylomicrons (Table 1) . Tracer studies in healthy humans without diabetes mellitus treated acutely with sitagliptin confirm that the predominant mechanism linking DPP-4 inhibition to reduction of circulating chylomicrons is by attenuation of intestinal lipoprotein production. 116 Although acute administration of GLP-1 delays gastric emptying and slows intestinal nutrient delivery, exenatide still inhibited intestinal lipoprotein production and secretion after intraduodenal nutrient delivery in human subjects 84 ( Table 1) . Because DPP-4Is do not slow gastric emptying, the major effect of these agents is on the synthesis and secretion of chylomicrons. 116 Proatherosclerotic chylomicron remnant particles were also reduced with exenatide treatment. 84 Levels of postprandial triglycerides may contribute to atherosclerotic risk. Excessive hepatic triglyceride deposition has been linked to increased cardiovascular risk in subjects with T2D. 118 Exenatide 90 and liraglutide 91 may reverse fatty liver disease (by ultrasonography criteria) or steatohepatitis (based on histological criteria), respectively (for details and references, see Table 1 ). It is difficult to conclude whether the main mechanism reflects body weight loss or changes in glucose, lipids, or mediators of inflammation. Studies with DPP-4Is have shown a reduction in hepatic triglyceride content with vildagliptin 92 and no significant effects with sitagliptin. 93 The mechanisms are unknown because most studies do not support the expression of GLP-1R in human hepatocytes.
Inflammation
GLP-1 94 and the GLP-1RA exenatide 95 reduce the generation of reactive oxygen species in endothelial 159 liraglutide, 160 dulaglutide, 161 and albiglutide 162 ). (B through G concern results reported for CVOTs). B, MACE. C, Acute myocardial infarction. D, Stroke. E, Cardiovascular death. F, All-cause death. G, Hospitalization for congestive heart failure (CHF) from cardiovascular outcomes trials. CVOT results have been published for saxgliptin, 34 alogliptin, 36 and sitagliptin 33 (DPP-4Is); and for lixisenatide, 80 liraglutide, 7 and semaglutide 8 (GLP-1 receptor agonists). MACE analysis in CVOTs may include hospitalization for unstable angina; acute myocardial infarction has variably been reported as all (fatal and nonfatal) or only nonfatal cases; stroke has been reported as ischemic or all stroke. See definition of end points for individual outcomes trials in Table 2 . BID indicates twice daily; CHF, congestive heart failure; CV, cardiovascular; and CVOT, cardiovascular outcome trial. cells and monocytes/macrophages. Although less well studied, acute and chronic administration of sitagliptin also reduced molecular markers of inflammation in circulating mononuclear cells from human subjects with T2D. 97 Specifically, nuclear factor κB binding in mononucleocytes was reduced by the exenatide 95 and sitagliptin. 97 GLP-1, GLP-1RAs (exenatide, liraglutide), and a DPP-4I (sitagliptin) reduced the production of inflammatory cytokines such as tumor necrosis factor-α, interleukins 1ß and 6, and intercellular adhesion molecules (Table 1) . Liraglutide reduced the expression of the inflammatory macrophage activation molecule sCD163 by 22%. 99 GLP-1RAs (exenatide, liraglutide) and a DPP-4Is (sitagliptin) also reduced levels of Creactive protein (Table 1) . Adiponectin, an adipocytokine that reduces insulin resistance, was increased by GLP-1RAs (exenatide and liraglutide) and DPP-4Is (sitagliptin and vildagliptin) ( Table 1) . Nevertheless, many of these studies are not controlled for changes in insulin or reductions in glycemia or body weight, and ascertainment of the underlying mechanisms coupling incretin therapy to reduced inflammation in humans is challenging.
Platelet Aggregation/Thrombosis
GLP-1r mRNA transcripts were detected in the human megakaryocyte MEG-1 cell line, which also exhibited functional cAMP accumulation in a dose-dependent manner in response to increasing concentrations of native GLP-1 and exenatide. 104 Whether isolated human platelets express a functional canonical GLP- 1R has not yet been definitively demonstrated, although Steven and colleagues 119 reported immunoreactive GLP-1R protein in murine and human platelets by Western blot analysis using a commercial antibody. In contrast, studies examining the human platelet transcriptome have failed to consistently detect GLP-1R expression. 120 Although GLP-1 receptor stimulation may have the potential to reduce platelet aggregation, only preliminary studies in humans have addressed potential effects on the stability of atherosclerotic plaques in general and in coronary vessels in particular. 121 Taken together, a large body of work demonstrates the effects of native GLP-1 and its degradation products, GLP-1RAs and DPP-4Is, in the cardiovascular system. These studies highlight potential mechanisms by which clinically meaningful modifications occur in the pathophysiology of coronary heart disease, acute myocardial infarction, congestive heart failure, and peripheral artery disease. The effects shown for GLP-1RAs and DPP-4Is appear to be qualitatively similar, whereas differences in effect sizes may occur. Comparative human studies characterizing quantitative differences between effects of GLP-1RAs and DPP-4Is are mostly lacking.
INFLUENCE OF GLP-1RAS AND DPP-4IS ON CARDIOVASCULAR RISK FACTORS
GLP-1RAs and DPP-4Is have been approved as glucoselowering agents for subjects with T2D. GLP-1RAs reduce fasting glucose concentrations substantially (by on average, up to 50 mg/dL) and HbA 1c by 0.5 to 1.3%, whereas DPP-4Is typically reduce fasting glucose concentrations by on average, up to 25 mg/dL and HbA 1c by 0.6% to 0.9% (Figure 1) . It is notable that GLP-1RAs with a short duration of action (achieving effective drug concentrations for less than a full 24-hour period) have smaller effects on fasting glucose and HbA 1c concentrations. Nevertheless, short-acting agents have more pronounced effects on gastric emptying and glycemic increments after a meal because they evade tachyphylaxis (for gastric emptying) typically induced by sustained exposure to high doses. 110 Because of the short-acting nature of lixisenatide leading to transient exposure to the drug after once-daily injection, effects on postprandial glycaemia are mainly present after the first meal following the subcutaneous injection of lixisenatide.
The glucose-dependent mechanism of modulating insulin and glucagon secretion confers incretin-based glucose-lowering medications with a low risk of hypoglycemia. 1 However, incretin therapies do not prevent hypoglycemic episodes prompted by other diabetes mellitus medications, especially when combined with sulfonylureas or insulin.
1,2 Nevertheless, DPP-4Is and GLP-1RAs have a lower risk for hypoglycemia when combined with sulfonylureas than is seen with insulin therapy. 144 Hypoglycemic episodes, especially severe hypoglycemic episodes (requiring third-party assistance for management) in population with T2D, are associated with increased risk of cardiovascular events and mortality. 145 GLP-1RAs typically lead to reductions in appetite and food intake resulting in a loss in body weight (Figure 1 ). The reduction in body weight achieved is usually between 2 and 4 kg on average 146 but may be highly variable. 146 DPP-4Is may lead to minor reduction in body weight but usually by <1 kg. 1, 2 GLP-1 can acutely lower nonesterified fatty acid concentrations through the stimulation of insulin and suppression of glucagon secretion, especially in patients with T2D and hyperglycemia. 82 In clinical trials, GLP1RAs have been shown to lower triglyceride concentrations and increase high-density lipoprotein cholesterol (ie, to ameliorate the dyslipidemia typically associated with insulin resistance) (Figure 1 ). Improvements in fasting triglycerides and high-density lipoprotein cholesterol may vary with the individual degree of weight reduction and glycemic control achieved but also between GLP1RAs. In addition, a small but consistent reduction in low-density lipoprotein cholesterol concentrations has been observed with GLP-1RAs, especially when com- paring this treatment modality to insulin regimens. 144 DPP-4Is do not have major effects on fasting lipoprotein patterns (Figure 1 ), although they do prevent or delay postprandial chylomicron formation, similar to findings with GLP-1RAs (Table 1) . ), and sodiumglucose cotransporter-2 inhibitors (empagliflozin 142 ). The cardiovascular safety trials performed to date have included human subjects with T2D at increased risk of cardiovascular events. Thus, subjects enrolled in these trials had prior cardiovascular events or presented with risk factors for cardiovascular events. Although this was not an explicit inclusion criterion, typically they had longstanding T2D, and a substantial proportion was treated with insulin (Table 2 ). To maintain glycemic equipoise, patients have been typically randomized to the therapy of interest or matching placebo, and investigators have been encouraged to monitor the hemoglobin A 1c in all patients and adjust glucose-lowering therapies accordingly. As a result of standard care allowing or even requiring changes in the glucose-lowering treatment in line with applicable guidelines, cardiovascular outcome studies are not useful for comparing glucose-lowering effects of different medications.
CARDIOVASCULAR OUTCOMES TRIALS WITH INCRETIN-DERIVED GLUCOSE-LOWERING MEDICATIONS
Cardiovascular Outcomes Trials With DPP-4Is
Saxagliptin, 34 alogliptin, 36 and sitagliptin 33 have been studied in appropriately powered cardiovascular outcomes trials (SAVOR-TIMI 53, EXAMINE, TECOS). Although all cardiovascular outcomes trials listed in Table 2 describe patients at high risk for cardiovascular events, the inclusion criteria varied substantially from individuals with a recent acute coronary syndrome to those with a previous history of cardiovascular events to subjects with only risk factors present at baseline. Nevertheless, the results of these studies of DPP-4Is on major adverse cardiovascular events have been similar. Inhibition of DPP-4 neither increased nor decreased the risk of the combined major adverse cardiovascular event outcome (Figure 2B ), which includes cardiovascular death (Figure 2E ), myocardial infarction ( Figure 2C ), or stroke ( Figure 2D ), including or not including hospitalization for unstable angina in the composite end point. Thus, the cardiovascular safety of these agents has been confirmed ( Figure 2B ).
In the SAVOR-TIMI 53 trial, patients randomized to saxagliptin had a 0.7% absolute increase in the risk of hospitalization for heart failure (3.5% versus 2.8%; HR, 1.27; 95% CI, 1.07-1.51). 35 In the EXAMINE trial, a greater number of patients treated with alogliptin were hospitalized for heart failure, but this difference was not statistically significant (3.1% versus 2.9%; HR, 1.07; 95% CI, 0.79-1.46). 37 However, in the TECOS trial, no difference occurred in the rates of hospitalization for heart failure (3.1% versus 3.1%; HR, 1.00; 95% CI, 0.84-1.20) 163 ( Figure 2G ). Subsequently, a large observational study did not find evidence that DPP-4 inhibition with either saxagliptin or sitagliptin was associated with hospitalization for heart failure. 164 A meta-analysis summarizing the risk for hospitalization because of congestive heart failure in cardiovascular outcomes trials indicated a nonsignificant elevation in risk (HR, 1.14; 95% CI, 0.97-1.34; P=0.10), 163 with substantial heterogeneity between trials with saxagliptin, 34 alogliptin, 36 and sitagliptin. 33 The lack of evidence for an effect of sitagliptin on heart failure, relative to the findings with saxagliptin and possibly alogliptin, may reflect differences in trial design or unique attributes of each drug and remains unexplained.
Cardiovascular Outcomes Trials With GLP-1RAs
The cardiovascular safety of GLP-1RAs has been evaluated in several randomized clinical trials. Lixisenatide was studied in 6068 patients with recent hospitalization for acute coronary syndrome. Neither an increase nor a decrease occurred in the risk of cardiovascular events with lixisenatide therapy ( Figure 2B ). 80 However, in separate studies, the longer-acting GLP-1RAs liraglutide and semaglutide reduced numbers of cardiovascular events. In the LEADER trial, 9340 patients at high risk of cardiovascular events (81% with established cardiovascular disease) were randomized to either liraglutide or (Figure 2 ). No significant difference in rates of hospitalization for heart failure occurred with liraglutide versus placebo in the LEADER trial (4.7% versus 5.3%; HR, 0.87; 95% CI, 0.73-1.05). These results are consistent with findings from a study in patients with more severe heart failure (baseline left ventricular ejection fraction ≤40%), which showed treatment with liraglutide over 180 days did not significantly change a mean global rank score evaluating time to death or hospitalization because of heart failure and changes in N-terminal probrain natriuretic peptide. 30, 165 However, the rates of hospitalization for heart failure in the patients treated with liraglutide in this study were numerically greater but not statistically different (41% [liraglutide] versus 34% [placebo]; HR, 1.30; 95% CI, 0.89-1.88).
Evidence for the cardiovascular benefit of GLP-1RAs was also seen with semaglutide, an investigational longacting, once-weekly GLP-1RA, in the SUSTAIN-6 trial. 8 This trial was designed as a noninferiority safety study and randomized 3297 patients with diabetes mellitus at high risk of cardiovascular disease (61% with established coronary artery disease). Treatment with semaglutide decreased the combined primary outcome of time to cardiovascular disease death, nonfatal myocardial infarction, or nonfatal stroke (6.6% versus 8.9%; HR, 0.74; 95% CI, 0.58-0.95). There was no difference in cardiovascular disease death (2.7% versus 2.8%; HR, 0.98; 95% CI, 0.65-1.48), and the reduction in the primary end point was driven by differences in myocardial infarction (2.9% versus 3.9%; HR, 0.74; 95% CI, 0.51-1.08) and stroke (1.6% versus 2.7%; HR, 0.61; 95% CI, 0.38-0.99). No statistically significant differences occurred in hospitalization for heart failure with semaglutide (3.6% [semaglutide] versus 3.3% [placebo]; HR, 1.11; 95% CI, 0.77-1.61) (Figure 2) .
Thus, these trials have demonstrated cardiovascular safety for GLP-1RAs. Two studies have shown significant reductions in cardiovascular events with liraglutide 7 and semaglutide 8 of 13% and 26%, respectively, whereas treatment with lixisenatide did not reduce cardiovascular events. The different results of these studies may reflect the unique pharmacology of the respective agents. For example, lixisenatide has a shorter duration of action than liraglutide and semaglutide. 110 Alternatively, differences in study design may be contributing. The ELIXA trial included only patients with a recent acute coronary syndrome, a condition associated with a particularly high risk for subsequent cardiovascular events.
Differences in study duration, patient risk profile, and study size may also influence trial-specific findings. Further studies, ideally head-to-head studies of GLP-1RAs, are needed to determine whether meaningful differences might explain these disparate findings.
WHAT MEDIATES BENEFICIAL CARDIOVASCULAR EFFECTS OF THE GLP-1RAS LIRAGLUTIDE AND SEMAGLUTIDE? Metabolic Results From Trials With GLP1RAs
Liraglutide and semaglutide were developed as glucoselowering medications for the treatment of patients with T2D. Semaglutide has not yet been approved. However, these agents also reduce body weight, systolic blood pressure, and, in some patients, triglyceride and lowdensity lipoprotein cholesterol.
1,2 Thus, although some have assumed that the cardiovascular effects found in the LEADER trial 7 and the SUSTAIN-6 trial 8 reflect differences in glucose/HbA 1c , it seems more likely that the reductions in cardiovascular events with these agents are driven by nonglycemic effects of these drugs. Liraglutide 7 and semaglutide 8 displayed the largest difference, relative to patients treated with placebos, in glycohemoglobin. The difference amounted to 0.40% (95% CI, 0.34-0.45) at 36 months but was larger (7.2% versus 8.2% with placebo) at 3 months with liraglutide. 7 With semaglutide, glycohemoglobin was lower by 0.66% (95% CI, 0.52-0.88) with the 0.5 mg dose and by 1.05% (95% CI, 0.91-1.19) with 1 mg per week. 8 This finding contrasts with the much smaller reduction in HbA 1c with lixisenatide (-0.27% [95% CI, -0.31 to -0.22]), although after 12 weeks this difference was larger (0.4%). 80 Small but significant weight loss occurred with lixisenatide (-0.7 [95% CI, -0.9 to -0.5] kg), 80 and more substantial weight loss occurred with liraglutide (-2.3 [95% CI, -2.5 to -2.0] kg) 7 and semaglutide (0.5 mg: -2.9 [-3. 8 Thus, significant reductions in cardiovascular events occurred with those treatments that induced the largest reductions in HbA 1c , body weight, and systolic BP. In addition, with liraglutide, a reduced risk for hypoglycemic episodes occurred, including severe hypoglycemic episodes. 7 This trend was observed with lixisenatide 80 but not with semaglutide. 8 Severe hypoglycemic episodes in patients with T2D have been linked to adverse cardiovascular and mortality outcomes.
Metabolic Results From Trials With DPP-4Is
In cardiovascular outcomes trials with the DPP-4Is saxagliptin, 34 alogliptin, 36 and sitagliptin, 33 differences in HbA 1c of <0.4% were uniformly observed because of the addition of glucose-lowering medications added as part of standard care in all patients. Furthermore, there was little difference in body weight, BP, and heart rate between patients treated with DPP-4Is and placebos.
Other Glucose-Lowering Medications Introduced as Part of Standard Care
Because liraglutide and semaglutide are potent glucoselowering agents and baseline HbA 1c concentrations in the LEADER 7 and SUSTAIN-6 8 trials were higher than common glycemic targets, additional glucose-lowering medications were added, more so in patients treated with placebo than in those treated with GLP-1RAs. Among those additional glucose-lowering medications were sulfonylureas and insulin. Observational studies have raised questions regarding the cardiovascular safety of sulfonylureas and insulin in patients at substantial risk for cardiovascular events. The propensity for these classes of glucose-lowering drugs to elicit (severe) hypoglycemic episodes is an additional concern. Further analyses of these outcomes trials may help indicate whether these added drugs may play a role in explaining the cardiovascular results.
Immediate Cardiovascular Effects of Stimulating GLP-1Rs
In meta-analyses of glucose-lowering trials, a significant reduction (by ≈15%) in the risk for acute myocardial infarction was shown when comparing intensive versus standard strategies for lowering glucose (representing an ≈0.9% difference in HbA 1c maintained over several years). 3, 166 There was no effect on stroke or (cardiovascular) death within the core duration of such trials. 3, 167 In some studies, a longer period of observation (>8 years) extending beyond the core trial period was necessary to show improvements in mortality, 168, 169 whereas in the LEADER trial, there was a significantly reduced cardiovascular and all-cause mortality within a shorter period of time. 7 When analyzing the combined results of glucose-lowering trials, there was more significant benefit for subjects with shorter diabetes mellitus duration, better glycemic control, and no cardiovascular diagnosis at baseline. 167 In contrast, in the LEADER and SUSTAIN-6 trials, patients with preexisting cardiovascular disease displayed trends toward a greater benefit from liraglutide 7 and semaglutide 8 treatment, compared with those patients with only baseline risk factors, although these differences were not significant. In addition, the magnitude of changes in glycohemoglobin, body weight, and systolic BP elicited by liraglutide and semaglutide were smaller and maintained for shorter periods of time than would be predicted to be sufficient to elicit cardiovascular benefits based on previous analyses of glucose-lowering strategies. 3, 167 The beneficial effects seen with liraglutide 7 and semaglutide 8 are consistent with diminishing atherogenic risk over time. The favorable within-trial changes seen in multiple cardiovascular risk factors (glycemia, body weight, systolic BP, lipids) (see Figure 1 ) may provide a conventional explanation for the results observed. However, previous analyses of glucose-lowering trials showed only a moderate reduction in myocardial infarction events with no change in (cardiovascular) mortality, 3 and even multifactorial interventions addressing BP (intensive management with antihypertensive medications), cholesterol (statins), and triglycerides (fibrates) reduced cardiovascular events, but not mortality 169 within a time frame similar to the duration of the cardiovascular outcomes trials with liraglutide (3.5 to 5 years) 7 and semaglutide (2 years). 8 Thus, it appears likely that traditional risk factor modification alone cannot explain the overall benefits observed, but rather additional mechanisms may be operative, most likely including direct effects in the cardiovascular system ( Table 1 ). The reductions in nonfatal acute myocardial infarction and nonfatal stroke with both liraglutide and semaglutide ( Figure 2 ) suggest a reduction of diabetes mellitus-related atherosclerotic disease, perhaps by reducing the plaque burden or increasing plaque stability. To date, however, no convincing evidence points to a single possible mechanism listed in Table 1 as playing a dominant role in the reduction of major adverse cardiovascular outcomes. Other potential mechanisms, such as reduced infarction-related myocardial necrosis ( Figure I in the online-only Data Supplement) with liraglutide or semaglutide treatment remain to be demonstrated. More careful characterization of the expression and function of GLP-1Rs in the cardiovascular system in patients with diabetes mellitus, coronary artery disease, or congestive heart failure seems prudent. Potential influences of GLP-1RAs on cardiovascular risk and function are depicted in Figure 3 .
Based on mechanistic findings in animals ( Table I in the online-only Data Supplement) and human subjects with and without diabetes mellitus (Table 1) , a beneficial effect of incretin-based medications on congestive heart failure was predicted, whereas only a (nonsignificant) trend for a reduction in the rate of hospitalization for congestive heart failure was observed in the LEADER trial, 7 with no similar observations from the other GLP-1RA trials, and some adverse outcomes from dedicated congestive heart failure trials with liraglutide 30 and detrimental findings with saxagliptin (DPP-4 I). 34, 35 No widely accepted explanation for this discrepancy exists. Changes in the pattern of GLP-1R expression accompanying the development of cardiac ischemia or left ventricular failure or enhanced susceptibility to tachyarrhythmias might offer potential explanations. More studies addressing these possibilities are needed. In contrast, the multitude of beneficial effects attributed to DPP-4 inhibition in mechanistic studies (Table 1) cannot easily be reconciled with the neutral results of large-scale clinical trials (Table 2, Figure 2 ). At this moment, no convincing explanation for this discrepancy exists. One possible explanation may reside in a different profile of potential DPP-4 substrates regulated by DPP-4Is in older humans with diabetes mellitus versus young animals with cardiovascular disease. A similar reasoning might explain potential mechanisms leading to worsening of congestive heart failure in some humans with DPP-4 inhibition. 34, 35 However, no specific candidate or differential profile of DPP-4 peptide(s) substrates has been identified that would provide a satisfactory explanation. Furthermore, it is similarly difficult to explain why some specific agents belonging to the DPP-4I class display an increased risk for hospitalization for congestive heart failure, whereas others seem to be free of such a risk.
CLINICAL PERSPECTIVE
The clinical implications dictate that long-acting GLP1RAs such as liraglutide (approved) and semaglutide (not yet approved) with demonstrated cardiovascular benefit should be used preferentially in human subjects matching the inclusion criteria of these cardiovascular outcomes trials. Their prescriptions should be weighed against that of empagliflozin (sodium-glucose cotransporter-1 inhibitor), which has shown benefits in terms of reducing (cardiovascular) mortality and hospitalization for congestive heart failure in similar populations of patients with T2D at high risk for cardiovascular events. 170 Information on cardiovascular outcomes with a combination treatment of GLP-1RAs and sodium-glucose cotransporter-2 inhibitors is not available.
In contrast, the cardiovascular safety of DPP-4Is has uniformly been underscored by neutral findings in cardiovascular outcomes trials with saxagliptin, alogliptin, and sitagliptin. Findings of an increased risk for hospitalization because of congestive heart failure with the DPP-4Is saxagliptin (significant) and alogliptin (nonsignificant trend) in the absence of clear benefits regarding overall cardiovascular risk require further mechanistic clarification and caution in using these drugs in individuals at risk for congestive heart failure.
OUTLOOK
Evidence that 2 GLP-1RAs, liraglutide and semaglutide, reduce major adverse cardiovascular events in subjects with T2D at high risk for such complications ( Figure 2 ) represents a major therapeutic advance. With these and additional glucose-lowering medications such as empagliflozin having a major impact on the risks for cardiovascular events and mortality, individualized treatment can be offered to patients with diabetes mellitus at risk for cardiovascular events. Whether there is a similar benefit for individuals at earlier stages of T2D with lower cardiovascular risk is not yet known. Continued research is needed to better define the mechanisms leading to the benefits seen to date (Table 3 ). It remains possible that the reductions in cardiovascular events seen in these trials are a direct result of GLP-1R signaling, given the numerous actions within the heart, blood vessels, and other tissues that impact risk factors (Table 1, Figure 1) . Irrespective of the underlying mechanisms, the neutral (in the case of DPP-4Is) and even beneficial (in the case of long-acting GLP-1RAs), cardiovascular actions of the incretin-based glucose-lowering medications have broadened our armamentarium, enabling application of personalized medicine to reduce the detrimental complications of T2D.
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